Summary.-The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, o subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81 % of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide a sensitive guide to tumour burden. CEA, lactalbumin and a subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.
ASSESSMENT of tumour burden remains reliably reflect tumour burden and that a major problem in the management of most patients with cancer. The measurement of tumour products such as human chorionic gonadotrophin (HCG) from choriocarcinoma or calcitonin from medullary carcinoma of the thyroid is invaluable in the early diagnosis, monitoring of therapy and detection of recurrence of these tumours. For breast cancer a satisfactory tumour marker or system of tumour markers would be of major clinical importance at all stages of the disease, and especially for early recognition of metastatic disease.
Although no single sensitive marker has so far been found for breast cancer, abnormalities of one or more tumourrelated substances have been reported in over 90% of patients with advanced disease (Franchimont 3t al., 1976; Tormey et al., 1975; Coombes et al., 1977) . To develop a multiparametric system for monitoring breast cancer, it is necessary to demonstrate that the components abnormal levels are great enough and frequent enough to be of clinical benefit.
The present study is an evaluation of the clinical usefulness of 8 potential tumour markers, selected because of reported abnormal levels in breast cancer. To define the relationship to tumour burden, serum concentrations of each potential marker were measured in patients with local disease before and after resection of primary disease, in patients with advanced disease and in a control population. In some patients, markers were estimated before and after progression or regression of advanced breast cancer. In addition, the proportion of tumours synthesizing the markers was defined by measuring the markers in extracts of primary breast tumours. . Cytosol was stored in aliquots until assayed and results were expressed per gram wet wt of tumour.
Tumour marker measurement.-The milk protein lactalbumin , carcinoembryonic antigen (CEA; Booth et al., 1974) , glycoprotein hormone cx subunit , P human chorionic gonadotrophin (HCG,B), calcitonin and thyroid-stimulating hormone (TSH) were measured by radioimmunoassay. Haptoglobin and pregnancy-associated a2 glycoprotein (PAG) were measured by rocket immunoelectrophoresis (Laurell, 1972) . Antiserum to HCGj3 subunit was raised in rabbits to purified HCG/ (CR115 kindly donated by R. E. Canfield) and used in a double-antibody radioimmunoassay ) in a dilution of 1:100,000. The limit of detectability (10% displacement) was 0-8 ,ug HCGfl/l and the within-and between-assay variations were 6% and 16% respectively.
Cross-reactivity at 50% displacement was: HCG 6%, LH 5%, TSH 1% (LH,B, LHMu, FSH, FSHP, FSHox, HCGoa less than 0-8%).
Calcitonin antiserum was raised in goats to synthetic calcitonin M (Ciba-Geigy) and used in a dilution of 1:40,000. TSH antiserum and reference standard TSH were obtained from N.I.A.M.D.D. Normal serum concentrations of markers were determined from healthy subjects (Table) . The limits of detectability of c subunit and CEA were 1-5 ,ug/l and 2-5 jug/l respectively.
RESULTS

Tumour products
CEA was detected in 41/60 (68%) breast-tumour cytosols (Fig. 3) in a range of 0-12-9-1 ,ug/g wet wt (mean= 1-65 ,ug/g wet wt). Raised serum levels of CEA ( Fig. 1) were significantly more common in either local or advanced disease than in controls (P < 0-01, P < 0-001 respectively remainder, CEA concentrations increased (P < 0-01) with tumour progression, and fell (P < 0 01) with tumour regression (Wilcoxon paired rank test). CEA change was appropriate to clinical change in 20 instances and inappropriate in 4. Of these 4, one patient had only marginally elevated CEA concentrations which did not change after mastectomy (16-+17 ,tg/l) and 2 patients died from disseminated disease within 3 months. In all 3 patients who developed early (<6 months) recurrence of breast cancer, postoperative CEA concentrations were raised (CEA= 20, 22 and 31 ,ug/l). Serum and cytosol CEA were measured in 36 patients. Ten patients had elevated serum concentrations either preoperatively or at the time of recurrence, and in all these CEA was detectable at a higher concentration in the primary tumour. In summary, CEA is detectable in a large proportion of primary breast carcinomas and is commonly found at raised levels in the serum of patients with advanced disease. Changes in raised serum CEA usually reflect changes in tumour burden.
Lactalbumin was detected in 43% of 93 tumour cytosols (range= 0 8-50 ng/g wet wt, mean= 9*6 ng/g wet wt disease, but in none of 29 age-and sexmatched controls (Fig. 3) . 
Markers in combination
CEA, lactalbumin and of subunit were measured in the same cytosol preparations of 52 breast cancers (Fig. 4) . One or more of the markers was detectable in 44 (84%). CEA, lactalbumin, a subunit and haptoglobin were each measured in the same serum samples from 21 patients with local and 53 patients with advanced breast cancer. One or more of the markers was greater than the upper limits of normal in 33% and 81% patients respectively. Many abnormal levels were just above the normal range, and marker concentrations greater than twice the upper limits of normal were found in 19% of local and 54% of advanced cancer patients. There was no significant association or dissociation between the detection of one marker and another in serum or cytosol. Some patients had several markers detectable in cytosol or abnormal in serum. In one patient who had a symptomatic and partial radiological response to adrenalectomy, preoperatively raised serum CEA (133 jug/l), lactalbumin (0.5 ,ug/l), cx subunit (42 Itg/l) and HCG/3 (4.0 ,ug/l) fell to 63, < 0 4, 13 and 2-9 jtg/l respectively. In another patient with disseminated disease, serum levels of lactalbumin, CEA and cx subunit were raised and all 3 markers were detected in cytosols from the primary tumour and an infiltrated axillary node.
DISCUSSION
CEA fulfils the initial requirements of a satisfactory tumour marker. Its levels are frequently raised, often to a considerable degree, and it is more commonly raised in advanced than in local disease. Previous studies report similar abnormalities of serum CEA in local and in advanced breast cancer, but whereas some (Steward et al., 1974; Tormey et al., 1977) found changes in CEA reflected progression or regression of disease in individual patients, Chu & Nemoto (1973) (Goldenberg et al., 1978) could be limited to those with CEA-positive primary tumours. The milk proteins casein and lactalbumin (Woods et al., 1979) have been examined as "appropriate products" in breast cancer. Perhaps because of the heterogeneity of casein, wide variation in abnormal levels is found (Monaco et al., 1979; Hendrick & Franchimont, 1974; .
We find no evidence to support suggestions that HCG3 Sheth et al., 1977) or calcitonin (Coombes et al., 1974) are commonly produced by breast tumours, or could be used as tumour markers in breast cancer. We found no definite cases of ectopic secretion of TSH, and high serum levels of TSH were probably due to hypothyroidism. We are unable to confirm the suggestion of a common thyroid disorder in breast cancer (Mittra & Haywood, 1974) .
Raised serum levels of acute-phase proteins have been described in association with a variety of carcinomas (Coombes et al., 1977; Bradwell et al., 1977) . In the present study, serum PAG was more commonly raised in patients with advanced than local disease, suggesting a relationship to tumour burden in a few individuals. Anderson et al. (1976) and Stimson (1975) reported that changes of PAG within the normal range are of predictive value in breast cancer. Our results show that changes of PAG within the normal range are a most unreliable guide to tumour burden and cannot be used as the basis for therapy.
Serum haptoglobin levels were more commonly raised in patients with advanced (40 %) than those with local (11%) breast cancer and appeared to be associated with rapidly progressive disease. However, the use of acute-phase proteins in breast cancer is likely to be limited because, irrespective of change in tumour burden, they may be affected by the interference of treatment with host responsiveness (e.g. surgery, radiotherapy and chemotherapy).
In combination a raised level of one or more markers was detected in 3400 patients with local breast cancer and 810%
with advanced disease. Measurement of additional tumour-indexing substances (Tormey et al., 1975; Coombes et al., 1977) might be expected to increase the proportion of patients with an abnormal level but would also increase the number of false-positive results. Markers of value in clinical management are usually present in serum in concentrations many times the normal (Bagshawe, 1974; Rosen et al., 1975) whereas the abnormal levels reported here are frequently less than twice, and rarely more than 10 times the upper limits of normal, and such abnormalities are unlikely to be sensitive guides to tumour burden. Although CEA is the best marker of breast cancer in this and other studies Tormey et al., 1975; Coombes et al., 1977) it is only abnormal in the serum of about 13% of patients with readily palpable primary breast tumours (many of which will have already metastasized); this indicates that even CEA is a crude index of tumour burden. The use of a combination of markers might provide some prediction of clinical change in advanced disease and assist patient assessment during drug trials, but it is unlikely to achieve any direct improvement in mortality or morbidity.
The relative insensitivity of the current markers is also indicated by the small proportion of patients with local disease who had abnormal concentrations. New and more sensitive tumour markers (probably tumour products) are required if minimal residual disease after mastectomy is to be detected. A theoretical alternative is the in vivo application of methods used in cell culture for stimulating tumour marker synthesis and release (Grieve et al., 1978; Lieblich et al. 1976 ).
We have found that CEA, lactalbumin and ax subunit are commonly detectable in breast-cancer cytosols. Our results confirm what might be expected, namely that the tumour products most frequently detected in cytosols (CEA, lactalbumin and of subunit) are most commonly abnormal in patients' sera, and that tumour concen-trations are greater than serum concentrations. Further information is required to define the relationship between tumour and serum concentration of markers, and between marker synthesis in primary and secondary tumours.
The identification of markers within primary tumours could become clinically important for several reasons. Firstly, the screening of patients for metastatic disease either by serum measurements of markers or by radioisotopic techniques might be best limited to patients with marker-positive primary tumours. Secondly, the presence of a marker may be related to a biological characteristic of clinical significance such as lactalbumin and hormonal responsiveness and HCG and prognosis (Horne et al., 1976) . Thirdly, the synthesis of tumour products by tumours grown in cell or tissue culture or transplanted into "nude" (immunosuppressed) mice is important in research into tumour differentiation and proliferation, and may be of clinical value if such methods are used to test tumour sensitivity to therapeutic regimes. The identification of 3 tumour products detectable in a total of 84% primary breast tumours may improve our understanding of breast cancer and ultimately aid patient management.
